Hypoglycemia Pipeline Review and Market Analysis, H2 2015

RnRMarketResearch.com adds ‘Hypoglycemia - Pipeline Review, H2 2015’, to its store. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

‘Hypoglycemia - Pipeline Review, H2 2015’ This report provides comprehensive information on the therapeutic development for Hypoglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects.

Purchase a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=415865 . (This is a premium report price at US$2000 for a single user PDF license)

Companies mentioned in this report are Biodel Inc., Eli Lilly and Company, Heptares Therapeutics Limited, Novartis AG, SkyePharma Plc, USV Limited, XERIS Pharmaceuticals, Inc., XOMA Corporation, Zealand Pharma A/S

Scope:

• The report provides a snapshot of the global therapeutic landscape of Hypoglycemia

• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

• The report reviews key players involved in the therapeutics development for Hypoglycemia and enlists all their major and minor projects

• The report summarizes all the dormant and discontinued pipeline projects

• A review of the Hypoglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and...